17:21 EDT Immuneering (IMRX) files $300M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering reports Q2 EPS (40c), consensus (40c)
- Immuneering granted atebimetinib patent by USPTO
- Immuneering price target raised to $10 from $8 at Mizuho
- Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly